BMJ4d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ4d
POS0835 EFFECTIVENESS AND SAFETY OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 57 PATIENTS
1 Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Division of Rheumatology, Santander, Spain 2 Hospital Universitario Donostia, Division of Rheumatology, Donostia, Spain 3 Hospital de ...
BMJ5d
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Correspondence to Dr Laura C Cappelli, Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA; lcappel1{at}jhmi.edu Objective We sought to investigate the long-term outcomes of ...
BMJ5d
SAT0073 MIR-186-5P targeting IL-33 gene as biomarker to predict subclinical atherosclerosis in patients with early rheumatoid arthritis
Background Patients with rheumatoid arthritis (RA) die prematurely compared with the general population, primarily because of cardiovascular diseases (CVD). Interleukin-33 (IL-33) is a member of the ...
BMJ5d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ4d
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis
Objective Innate lymphoid cells-2 (ILC2) were shown to be involved in the development of lung or hepatic fibrosis. We sought to explore the functional and phenotypic heterogeneity of ILC2 in skin ...
BMJ9d
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
Objectives To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and ...
BMJ17d
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ9d
EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis
15 Department of Radiology. Leiden University Medical Centre, Leiden, The Netherlands 16 Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands ...
BMJ10d
OP0023 GENERATION OF PT101, A HIGHLY SELECTIVE IL-2 MUTEIN FOR TREATMENT OF AUTOIMMUNE DISEASES
4 Pandion Therapeutics, Translational Sciences, Watertown, United States of America 5 Pandion Therapeutics, R&D, Watertown, United States of America Background: Regulatory T cells (Tregs) play a ...
BMJ6d
OP0157 CCL2-CCR2 AXIS MEDIATES DECIDUAL MONOCYTE/MACROPHAGE INFILTRATION AND INFLAMMATION IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME
1 West China Second University Hospital, Sichuan University, The Reproductive Medical Center, Department of Obstetrics and Gynecology, Chengdu, China 2 The Third Affiliated Hospital of Sun Yet-Sen ...
BMJ9d
Quadriceps weakness in knee osteoarthritis: the effect on pain and disability
a Rheumatology Unit, City Hospital, Nottingham NG5 1PB, b Department of Public Health Medicine and Epidemiology, Queens Medical Centre, Nottingham Dr O’Reilly. OBJECTIVES (1) To determine the ...